Document is current

Any future updates will be listed below

1340 BT7455, a fully synthetic <i>Bicycle</i> tumor-targeted immune cell agonist<sup>®</sup>, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.1340

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark